↓ Skip to main content

The Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome by Downregulating miRNA that Target Inflammatory Pathways

Overview of attention for article published in Frontiers in Pharmacology, April 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
7 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
18 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome by Downregulating miRNA that Target Inflammatory Pathways
Published in
Frontiers in Pharmacology, April 2021
DOI 10.3389/fphar.2021.644281
Pubmed ID
Authors

Muthanna Sultan, Hasan Alghetaa, Amirah Mohammed, Osama A. Abdulla, Paul J. Wisniewski, Narendra Singh, Prakash Nagarkatti, Mitzi Nagarkatti

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 17%
Student > Doctoral Student 2 11%
Student > Ph. D. Student 2 11%
Student > Master 2 11%
Other 1 6%
Other 3 17%
Unknown 5 28%
Readers by discipline Count As %
Medicine and Dentistry 5 28%
Immunology and Microbiology 4 22%
Biochemistry, Genetics and Molecular Biology 3 17%
Agricultural and Biological Sciences 1 6%
Unknown 5 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2022.
All research outputs
#8,463,406
of 25,874,560 outputs
Outputs from Frontiers in Pharmacology
#3,911
of 20,034 outputs
Outputs of similar age
#176,698
of 457,259 outputs
Outputs of similar age from Frontiers in Pharmacology
#204
of 903 outputs
Altmetric has tracked 25,874,560 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 20,034 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 457,259 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 903 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.